Toxicogenomics
Toxicogenomics is a subdiscipline of
Pharmaceutical research
In pharmaceutical research, toxicogenomics is defined as the study of the structure and function of the genome as it responds to adverse xenobiotic exposure. It is the toxicological subdiscipline of pharmacogenomics, which is broadly defined as the study of inter-individual variations in whole-genome or candidate gene single-nucleotide polymorphism maps, haplotype markers, and alterations in gene expression that might correlate with drug responses.[3][4] Though the term toxicogenomics first appeared in the literature in 1999,[5] it was by that time already in common use within the pharmaceutical industry as its origin was driven by marketing strategies from vendor companies. The term is still not universally accepted, and others have offered alternative terms such as chemogenomics to describe essentially the same field of study.[6]
Bioinformatics
The nature and complexity of the data (in volume and variability) demands highly developed processes of automated handling and storage. The analysis usually involves a wide array of bioinformatics and statistics,[7] often including statistical classification approaches.[8]
Drug discovery
In pharmaceutical
Public projects
Chemical Effects in Biological Systems is a project hosted by the National Institute of Environmental Health Sciences building a knowledge base of toxicology studies including study design, clinical pathology, and histopathology and toxicogenomics data.[10][11]
InnoMed PredTox assesses the value of combining results from various omics technologies together with the results from more conventional toxicology methods in more informed decision-making in preclinical safety evaluation.[12]
Open TG-GATEs (Toxicogenomics Project-Genomics Assisted Toxicity Evaluation System) is a Japanese public-private effort which has published gene expression and pathology information for more than 170 compounds (mostly drugs).[13]
The Predictive Safety Testing Consortium aims to identify and clinically qualify safety biomarkers for regulatory use as part of the
ToxCast is a program for Predicting Hazard, Characterizing Toxicity Pathways, and Prioritizing the Toxicity Testing of Environmental Chemicals at the United States Environmental Protection Agency.[14]
Tox21 is a federal collaboration involving the National Institutes of Health (NIH), Environmental Protection Agency (EPA), and Food and Drug Administration (FDA), is aimed at developing better toxicity assessment methods.[15] Within this project the toxic effects of chemical compounds on cell lines derived from the 1000 Genomes Project individuals were assessed and associations with genetic markers were determined.[16] Parts of this data were used in the NIEHS-NCATS-UNC DREAM Toxicogenetics Challenge in order to determine methods for cytotoxicity predictions for individuals.[17][18]
See also
- Comparative Toxicogenomics Database
- Pharmacogenetics
- Structural genomics
References
- PMID 20669449.
- PMC 1247673.
- S2CID 33145913.
- S2CID 5902873.
- PMID 10204799.
- S2CID 24834075.
- PMID 15033600. Archived from the originalon 2008-07-04.
- PMID 17689568.
- PMID 16507466. Archived from the originalon 2008-10-17.
- S2CID 1368324.
- S2CID 27489795.
- ^ PMID 18449490.
- PMID 25313160.
- PMID 16963515.
- ^ "Toxicology in the 21st century project". www.ncats.nih.gov.
- PMID 25622337.
- ^ "NIEHS-NCATS-UNC-DREAM Toxicogenetics Challenge". Sage Bionetworks.
- ^ "DeepTox: Deep Learning for Toxicity Prediction". Institute of Bioinformatics, Johannes Kepler University Linz.
External links
- Center for Research on Occupational and Environmental Toxicology definition by the CROET Research Centers: (Neuro)toxicogenomics and Child Health Research Center.